Clinical trial
An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions
NCT04591535 is registered in ClinicalTrials.gov with Hong Kong WD Pharmaceutical Co., Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Balanced, Randomised, Four-treatment, Four-period, Four-sequence, Single Oral Dose, Crossover PK Study of WD-1603 in Normal, Healthy, Adult Human Subjects Under Fed Conditions
- Lead sponsor
- Hong Kong WD Pharmaceutical Co., Limited
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- September 28, 2020
- Completion date
- March 28, 2021
- Enrollment
- 8 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.